Drugmakers Amgen Inc. and Horizon Therapeutics are developing treatments for systemic lupus erythematosus and atopic dermatitis, and their pipeline crossover is a likely area of investigation in the US Federal Trade Commission’s second-request inquiry regarding their deal. Both Amgen and Horizon are in the clinical trial phase of research and
* = Required Field
*Areas of Interest
MLex content is primarily organized into different areas of interest that cover the main elements of regulatory risk. Please indicate which ones you would like to be included in your Daily Wrap-up alert
MLex Limited and our LexisNexis Legal & Professional group of companies will use your personal information to administer your account and/or provide the products and services that you have requested from us. We may also contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center . You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy .